Mizuho Maintains Outperform on Medpace Holdings, Raises Price Target to $700

Mizuho analyst Ann Hynes has maintained an 'Outperform' rating on Medpace Holdings (NASDAQ: MEDP) and raised the price target from $665 to $700. This adjustment reflects a positive outlook on the company's performance.